Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Managing Toxicities of Ropeginterferon Alpha-2b in Patients With PV

September 1st 2023

Joe Scandura, MD, PhD, summarizes the toxicity profile of interferon therapy in patients with polycythemia vera.

Managing Toxicities of Hydroxyurea in Patients With PV

September 1st 2023

Drs John Mascarenhas and Joe Scandura review the toxicities seen with the non-specific chemotherapeutic agent hydroxyurea in patients with polycythemia vera.

Dr Halpern on Addressing Unmet Needs in Myelofibrosis

August 29th 2023

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Dr Platzbecker on the FDA Approval of Luspatercept in Lower-Risk MDS

August 29th 2023

Uwe Platzbecker, MD, discusses the significance of the FDA approval of luspatercept for patients with lower-risk myelodysplastic syndrome with anemia.

FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

August 29th 2023

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis stimulating agent (ESA) use in adult patients with very low– to intermediate-risk myelodysplastic syndrome (MDS) who may require regular red blood cell (RBC) transfusions.

Dr Halpern on the Investigation of Upfront Ruxolitinib and Navitoclax in Myelofibrosis

August 28th 2023

Anna B. Halpern, MD, discusses investigational efforts to utilize ruxolitinib and navitoclax in earlier treatment lines for patients with myelofibrosis.

Komrokji Examines Differences Between the WHO and ICC MDS Criteria

August 28th 2023

Rami Komrokji, MD, discusses an international dataset analysis of the 2 current classification systems for patients with myelodysplastic syndromes, as well as the next steps being taken to develop a more harmonized classification system.

Dr Kremyanskaya on the Safety of Rusfertide in Phlebotomy-Dependent PV

August 25th 2023

Marina Kremyanskaya, MD, PhD, discusses the safety profile and future implications of rusfertide in the treatment of patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Factoring Symptom Burden Into Treatment Decision-Making for Patients With PV

August 25th 2023

Joe Scandura, MD, PhD, explains how he considers individual symptom burden when deciding on a treatment regimen for a patient with polycythemia vera.

Reducing Risk of Thrombosis in Patients With PV

August 25th 2023

Key opinion leaders discuss their treatment targets for low- and high-risk patients with polycythemia vera.

Dr Kremyanskaya on the Promise of Rusfertide in Phlebotomy-Dependent PV

August 24th 2023

Marina Kremyanskaya, MD, PhD, discusses the potential advantages of using rusfertide to treat patients with phlebotomy-dependent polycythemia vera, as seen in the phase 2 REVIVE trial.

Dr Mascarenhas on the Goals of the Phase 1/2 KRT-232-109 Study in Myelofibrosis

August 21st 2023

John Mascarenhas, MD, discusses the goals of the phase 1/2 KRT-232-109 study evaluating the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis and highlights the eligibility criteria of this trial.

FDA Accepts NDA for Imetelstat in Lower-Risk MDS

August 21st 2023

The FDA has accepted a new drug application seeking the approval of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome.

Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies

August 18th 2023

Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.

Importance of Bone Marrow Biopsy For Diagnosis of PV

August 18th 2023

Experts explain the critical importance of obtaining bone marrow biopsies for accurately diagnosing polycythemia vera.

Typical Presentation of a Patient With PV

August 18th 2023

John Mascarenhas, MD, and Joe Scandura, MD, PhD, detail the typical presentation of a patient with polycythemia vera in their clinical practices.

Dr Mascarenhas on the Rationale for the KRT-232-109 Study in Secondary Myelofibrosis

August 17th 2023

John Mascarenhas, MD, discusses the rationale for adding the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in patients receiving treatment for primary or secondary myelofibrosis who have previously had suboptimal responses with ruxolitinib.

Final Thoughts on Recent Data Updates in MDS

August 17th 2023

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia

August 15th 2023

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Reducing Risk of Disease Progression in Patients With PV

August 11th 2023

Dr Joe Scandura discusses how he considers risk of disease progression when during therapeutic decision making for a patient with polycythemia vera.